NASDAQ:ONC BeOne Medicines 5/7/2025 Earnings Report $306.05 +8.09 (+2.72%) As of 08/29/2025 04:00 PM Eastern ProfileEarnings HistoryForecast BeOne Medicines EPS ResultsActual EPS$1.22Consensus EPS -$0.71Beat/MissBeat by +$1.93One Year Ago EPSN/ABeOne Medicines Revenue ResultsActual Revenue$1.12 billionExpected Revenue$1.12 billionBeat/MissMissed by -$7.30 millionYoY Revenue GrowthN/ABeOne Medicines Announcement DetailsQuarterDate5/7/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile BeOne Medicines Earnings HeadlinesAnalysts Set BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Price Target at $330.893 hours ago | americanbankingnews.comBeOne Medicines stock rises after positive Phase 1/2 results2 hours ago | za.investing.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. | Brownstone Research (Ad)BeOne Medicines stock rises after positive Phase 1/2 results2 hours ago | in.investing.comBeOne Medicines succeeds in Phase 1/2 study for lymphoma therapy2 hours ago | msn.comBeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)August 29 at 6:00 AM | businesswire.comSee More BeOne Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email. Email Address About BeOne MedicinesBeOne Medicines (NASDAQ:ONC) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation cancer immunotherapies. The company’s core focus lies in engineering T-cell engager antibodies designed to recruit and activate a patient’s own immune system against solid tumors. By leveraging a proprietary platform for bispecific antibody design, BeOne Medicines aims to create therapies with enhanced specificity and safety profiles compared with conventional approaches. The company’s pipeline comprises multiple early-stage programs directed at validated tumor-associated antigens. These candidates are advancing through preclinical studies, with plans to initiate first-in-human trials in the near term. BeOne Medicines applies a rational target selection process and modular antibody format to optimize pharmacokinetics and tumor penetration, seeking to address unmet needs in indications that have shown limited response to existing treatments. Guided by a multidisciplinary management team with extensive experience in oncology drug development, BeOne Medicines collaborates with leading academic institutions and contract research organizations to accelerate its programs. The company maintains strategic partnerships to support process development, manufacturing, and regulatory strategy, positioning it to progress its immuno-oncology candidates toward clinical milestones and potential commercialization.Written by Jeffrey Neal JohnsonView BeOne Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost Pressures Upcoming Earnings Salesforce (9/3/2025)Broadcom (9/4/2025)Oracle (9/8/2025)Synopsys (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
